Antiphospholipid Syndrome (APS) is defined by thrombosis and/or pregnancy morbidity in patients with antiphospholipid antibodies.
The Problem
Thrombotic APS is characterized by venous, arterial, or microvascular thrombosis. These patients with require indefinite anticoagulation, and warfarin has historically been the standard treatment.
There remains a pressing need for identification of clinical and laboratory parameters that define patients at most considerable risk for APS-related events on Direct oral anticoagulants (DOACs).
Our Solution
We are developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.
Designed using a retrometabolic drug design process which targets a different pathway than the most commonly prescribed drugs used in the treatment of certain medical conditions requiring chronic anticoagulation, potentially gives tecarfarin a better safety profile and potentially eliminates specific side effects while maintaining or improving efficacy.
PREVALENCE
Need content
